Types of Cancer We Treat

Melanoma

As one of the first skin cancer treatment programs in New York City, we have long been at the forefront of melanoma research and care. We created the ABCDE screening system—now a standard diagnostic tool—to help identify melanoma at an early stage, when treatment is most effective.

Our dermatologists, dermatopathologists, oncologic surgeons, reconstructive plastic surgeons, medical oncologists, radiation oncologists, and pathologists combine their expertise to customize a treatment plan for you.

Our melanoma surgeons specialize in removing the cancer while preserving appearance and function, and our medical oncologists provide the latest targeted treatments, including genetically engineered injectable therapies.

Find a Doctor & Schedule
Diagnosis
Surgery
Targeted Drugs & Immunotherapy
Radiation Therapy

Related News

Promising New Treatment for Advanced Melanoma
Read Story
Clinical Trial Tests Adjuvant Immunotherapy for Melanoma
Read Story
How the Microbiome & Checkpoint Inhibitors Are Connected
Read Story
New Immunotherapy Drug Shows Promise Against Several Cancers
Read Story
Researcher Seeks to Understand Cancer Metastasis Mechanisms
Read Story
Clinical Trials Led to FDA-Approved Cancer Drugs in 2021
Read Story
Skin Cancer Cells Need Alzheimer’s Disease Protein to Thrive
Read Story
Immunotherapy After Surgery Could Prevent Return of Melanoma
Read Story
Melanoma Expert Discusses New Clinical Trial Results
Read Story
Meet the Team That Conquered Skin Cancer at Its Most Complex
Read Story
Cancer Scientists Discuss Melanoma & Lung Cancer Research
Read Story
Oncolytic Virus Shows Early Success Against Melanoma
Read Story

Clinical Trials and Research Studies

Phase 2

MONETTE: A Randomised Open-Label Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition

Learn More

Phase 1

A Phase 1/1b Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors.

Learn More

Phase 3

Melanoma Margins Trial (MelMarT): A Phase III Multi-Centre Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.

Learn More

Phase 5

Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C

Learn More
View All Related Clinical Trials (19)